Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ICER's Ambitious 2018 Review Agenda Takes On Groundbreaking Treatments

Executive Summary

Institute for Clinical and Economic Review plans to evaluate the cost effectiveness of gene therapy, CAR-T drugs and tissue-agnostic cancer drugs, among other treatments, in 2018.


Related Content

$1M For Luxturna? ICER Says Big Discount Needed To Be Cost Effective
Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS
Policy Prescriptions: Kite's CAR-T; Price And Value Scrutiny; Biosimilars; Manufacturing Missteps
Momentum Builds For Tomorrow's More Convenient Hemophilia Drugs
Novartis' CAR-T Poised For The Market After Unanimous FDA Adcomm Review
ICER Eyes Gene Therapy: Category-wide Policy In Works As Spark Moves To Approval
Loxo Sees Larotrectinib As Model Form Of Oncology Drug Development
Teva Clinches Third Place In CGRP Race With A Phase III Migraine Win
Kite On Course For FDA Filing On Positive CAR-T Durability Data


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts